Next Article in Journal
Enhancement of Bone-Forming Ability on Beta-Tricalcium Phosphate by Modulating Cellular Senescence Mechanisms Using Senolytics
Previous Article in Journal
Reduction of Oxidative Stress in Peripheral Blood Mononuclear Cells Attenuates the Inflammatory Response of Fibroblast-like Synoviocytes in Rheumatoid Arthritis
Article

Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19

1
Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei 11529, Taiwan
2
Institute of Cellular and Organismic Biology, Academia Sinica, Taipei 11529, Taiwan
*
Author to whom correspondence should be addressed.
These authors contributed equally.
Academic Editor: Nuno Taveira
Int. J. Mol. Sci. 2021, 22(22), 12412; https://doi.org/10.3390/ijms222212412
Received: 4 October 2021 / Revised: 13 November 2021 / Accepted: 14 November 2021 / Published: 17 November 2021
(This article belongs to the Section Molecular Microbiology)
Mitigation strategies of the coronavirus disease 2019 (COVID-19) pandemic have been greatly hindered by the continuous emergence of SARS-CoV-2 variants. New sensitive, rapid diagnostic tests for the wide-spectrum detection of viral variants are needed. We generated a panel of 41 monoclonal antibodies against the SARS-CoV-2 nucleocapsid protein (NP) by using mice hybridoma techniques. Of these mAbs, nine exhibited high binding activities and were applied in latex-based lateral flow immunoassays (LFIAs). The LFIAs utilizing NP-mAb-7 and -40 had the best sensitivity and lowest limit of detection: 8 pg for purified NP and 625 TCID50/mL for the authentic virus (hCoV-19/Taiwan/4/2020). The specificity tests showed that the NP-mAb-40/7 LFIA strips did not cross-react with five human coronavirus strains or 20 other common respiratory pathogens. Importantly, we found that 10 NP mutants, including alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617.2) variants, could be detected by NP-mAb-40/7 LFIA strips. A clinical study (n = 60) of the NP-mAb-40/7 LFIA strips demonstrated a specificity of 100% and sensitivity of 90% in infected individuals with cycle threshold (Ct) values < 29.5. These anti-NP mAbs have strong potential for use in the clinical detection of SARS-CoV-2 infection, whether the virus is wild-type or a variant of concern. View Full-Text
Keywords: COVID-19; SARS-CoV-2; antibody; nucleocapsid protein; rapid test; LFIA COVID-19; SARS-CoV-2; antibody; nucleocapsid protein; rapid test; LFIA
Show Figures

Figure 1

MDPI and ACS Style

Lu, R.-M.; Ko, S.-H.; Chen, W.-Y.; Chang, Y.-L.; Lin, H.-T.; Wu, H.-C. Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19. Int. J. Mol. Sci. 2021, 22, 12412. https://doi.org/10.3390/ijms222212412

AMA Style

Lu R-M, Ko S-H, Chen W-Y, Chang Y-L, Lin H-T, Wu H-C. Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19. International Journal of Molecular Sciences. 2021; 22(22):12412. https://doi.org/10.3390/ijms222212412

Chicago/Turabian Style

Lu, Ruei-Min, Shih-Han Ko, Wan-Yu Chen, Yu-Ling Chang, Hsiu-Ting Lin, and Han-Chung Wu. 2021. "Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19" International Journal of Molecular Sciences 22, no. 22: 12412. https://doi.org/10.3390/ijms222212412

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop